AI Verdict
MEOBF has stronger fundamentals based on our AI analysis.
MEOBF vs MED Fundamental Comparison
| Metric | MEOBF | MED |
|---|---|---|
| Revenue | N/A | $385.8M |
| Net Income | N/A | $-18.7M |
| Net Margin | N/A | -4.8% |
| ROE | N/A | -9.4% |
| ROA | N/A | -7.5% |
| Current Ratio | N/A | 4.69x |
| Debt/Equity | N/A | 0.00x |
| EPS | N/A | $-1.70 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MEOBF vs MED: Frequently Asked Questions
Is MEOBF or MED a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MEOBF has stronger fundamentals. MEOBF is rated HOLD (5% confidence) while MED is rated SELL (85% confidence). This is not investment advice.
How does MEOBF compare to MED fundamentally?
MESOBLAST LTD has ROE of N/A vs MEDIFAST INC's -9.4%. Net margins are N/A vs -4.8% respectively.
Which stock pays higher dividends, MEOBF or MED?
MEOBF has a dividend yield of N/A or no dividend while MED has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MEOBF or MED for long term?
For long-term investing, consider that MEOBF has HOLD rating with 5% confidence, while MED has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MEOBF vs MED?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MEOBF vs MED, the AI consensus favors MEOBF based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.